Clinical Trials Browser

Phase 2/3 × INDUSTRY × blinatumomab × Clear all

NCT07570173 2026-06-05

MK-1045-005

Phase 2/3 Recruiting

Burkitt Lymphoma

NCT02910063 2021-01-13

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

Phase 2/3 Completed

41 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Lymphoma, B-Cell